earnings
confidence high
sentiment positive
materiality 0.75
ANI Pharma prelim Q4/FY24 Cortrophin Gel rev $197.8-198.4M; FY25 rev guidance $739-759M
ANI PHARMACEUTICALS INC
2024-FY EPS reported
-$1.04
revenue$614,376,000
- Cortrophin Gel net rev Q4: $59.2-59.8M; FY24: $197.8-198.4M.
- ILUVIEN/YUTIQ net rev Q4: $26.6-27.2M; post-acquisition period (Sep 16-Dec 31): $30.4-31.0M.
- FY24 total rev, adjusted EBITDA, adjusted EPS expected at or above guidance issued Nov 8, 2024.
- FY25 outlook: total rev $739-759M (24-27% growth vs FY24 midpoint); adj EBITDA $182-192M.
- Full FY24 and detailed FY25 guidance to be reported in late Feb 2025 earnings call.